Pharsight

Lytgobi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(8 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833151 TAIHO ONCOLOGY Pharmaceutical composition including sodium alkyl sulfate
Nov, 2039

(15 years from now)

Lytgobi is owned by Taiho Oncology.

Lytgobi contains Futibatinib.

Lytgobi has a total of 3 drug patents out of which 0 drug patents have expired.

Lytgobi was authorised for market use on 30 September, 2022.

Lytgobi is available in tablet;oral dosage forms.

Lytgobi can be used as method of treating intrahepatic cholangiocarcinoma.

Drug patent challenges can be filed against Lytgobi from 30 September, 2026.

The generics of Lytgobi are possible to be released after 05 November, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 30, 2027
Orphan Drug Exclusivity(ODE-410) Sep 30, 2029

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 30 September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET;ORAL

More Information on Dosage

LYTGOBI family patents

Family Patents